Skip to main content
Clinical Trials/NCT01226654
NCT01226654
Terminated
Not Applicable

Quantitative MR Imaging and Proton Spectroscopy in MS

NYU Langone Health1 site in 1 country69 target enrollmentAugust 1991

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Multiple Sclerosis
Sponsor
NYU Langone Health
Enrollment
69
Locations
1
Primary Endpoint
Assess the MS lesions using Magnetization transfer ratio histogram parameters and compare it to total brain parenchymal volume
Status
Terminated
Last Updated
8 years ago

Overview

Brief Summary

The primary purpose of this study is to detect changes in the brain that may be associated with multiple sclerosis. Results will be compared to age matched controls. Investigators will assess lesions by measuring T2 and T1 enhanced lesion volumes and magnetization transfer ratio histogram parameters (MTRHP) in patients with relapsing-remitting and secondary-progressive disease. This data will be correlated to total brain parenchymal volume as well as identifying the effect of MS lesions on the gray and white matter, volumetric disability, including Kurtzke Expanded Disability Status Scale (EDSS) and a specific battery of neuropsychological tests. Quantitative analysis of whole brain N-acetylaspartate (WBNAA), a reproducible measure of viable neuron number, using 1H MRS and compare the results to age-matched controls over duration of 5 years.

Registry
clinicaltrials.gov
Start Date
August 1991
End Date
April 2016
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients with known MS diagnosis
  • Age 7-110 years
  • Males or females

Exclusion Criteria

  • Medically unstable
  • Artificial implants in the body
  • Normal Controls

Outcomes

Primary Outcomes

Assess the MS lesions using Magnetization transfer ratio histogram parameters and compare it to total brain parenchymal volume

Time Frame: 5 years

1) Lesions will be assessed by measuring T2 and T1 enhanced lesion volumes and magnetization transfer ratio histogram parameters (MTRHP) in patients with relapsing-remitting and secondary-progressive disease. This data will be correlated to total brain parenchymal volume as well as identifying the effect of MS lesions on the gray and white matter, volumetric disability, including Kurtzke Expanded Disability Status Scale (EDSS) and a specific battery of neuropsychological tests

Secondary Outcomes

  • Quantitative analysis of whole brain N-acetylaspartate (WBNAA)(5 years)

Study Sites (1)

Loading locations...

Similar Trials